Most BPC-157 evidence comes from laboratory and animal studies. Human evidence is extremely limited, so claims about injury healing, gut repair or recovery in people remain unproven.
Still uncertain: Whether it improves injury healing in people, the best route, long-term safety and the overall balance of benefits and risks are not established.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Synthetic 15-amino-acid peptide
Entity type
Peptide
Research focus
Musculoskeletal injury, gastrointestinal and wound-healing research
Human evidence
Human evidence remains extremely limited. A 2025 systematic review found 35 preclinical studies and only one clinical study; a later retrospective real-world preprint cannot establish efficacy. GI and injury-healing claims remain dominated by animal/preclinical research.
Regulatory status
Not FDA-approved; FDA has highlighted safety-information gaps for compounded BPC-157.
Main limitations
Efficacy for injury healing in humans, optimal route, long-term safety and benefit-risk are not established.
Safety
Human safety is poorly characterised; FDA highlights potential immunogenicity, peptide impurities and limited safety information.
Evidence reviewed
2026-09-18
i
Human evidence remains extremely limited. A 2025 systematic review found 35 preclinical studies and only one clinical study; a later retrospective real-world preprint cannot establish efficacy. GI and injury-healing claims remain dominated by animal/preclinical research.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Human safety is poorly characterised; FDA highlights potential immunogenicity, peptide impurities and limited safety information.
Technical details
Mechanism / biologyProposed effects involve angiogenic, nitric-oxide, inflammatory and tissue-repair signalling; exact human mechanism is unestablished.
Route / formulation boundaryResults from animal models cannot be presented as proven human healing effects. Research-grade product quality varies.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceHuman pilot regimen verified. A two-participant IV safety pilot used 10 mg on day 1 and 20 mg on day 2 as one-hour infusions. This does not establish an effective, subcutaneous or long-term human dose.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
3outcome records
8linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
